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A commentary on
Inflammasome-mediated dysbiosis regu-
lates progression of NAFLD and obesity
by Henao-Mejia, J., Elinav, E., Jin, C., Hao,
L., Mehal, W. Z., Strowig, T., et al. (2012).
Nature 482, 179–185.
Non-alcoholic fatty liver disease (NAFLD)
is a manifestation of metabolic syndrome,
a group of conditions including hyperten-
sion, high plasma glucose, excess body fat
around waist or abnormal cholesterol lev-
els which will work together to increase the
risk of heart disease, diabetes, and stroke
(Kim and Younossi, 2008). Although 20%
of NAFLD cases progress to non-alcoholic
steatohepatitis (NASH), the exact cause of
the disease progression is uncertain (Lucy
Bird, 2012; Ibrahim et al., 2013). Gut and
liver are connected via the portal circu-
lation and through embryogenesis they
are clearly linked. Researchers hypoth-
esized that due to this link, imbalances
in the gut could influence liver disease.
Normal gut flora plays a significant role in
keeping our innate immune system intact
and when dysbiosis occurs, it may lead
to various inflammatory diseases (Wood,
2012). Inflammasomes are recently discov-
ered multiprotein complexes involved in a
diverse range of inflammatory patholo-
gies (Kolliputi et al., 2010, 2012). A
specific inflammasome sensor consists
of nucleoside-triphosphatase domain
(NACHT), leucine rich repeat (LRR),
and pyrin domain (PYD), which are
domains-containing protein 3 (NLRP3)
(Lane et al., 2013; Qazi et al., 2013).
Toll-like receptors (TLRs) are a different
subset of “danger-sensing” receptors that
trigger proinflammatory gene expression
(Janssens and Beyaert, 2003).
An exciting but different way at looking
at the progression of NAFLD to NASH
has been conducted by Henao-Mejia
et al. (2012). Though the association
between intestinal dysbiosis and progres-
sion of FLD has been studied in the past,
Henao-Mejia et al. now suggest that gut
dysbiosis may be the driver of this pro-
gression, not just an association. To carry
out this study, the researchers looked at
the inflammasomes NLRP6 and NLRP3,
and a cytokine, Interleukin-18 (IL-18).
Since the major aim of this study was
to determine the cause of progression
of NAFLD in Metabolic Syndrome, mice
were fed a methionine-choline-deficient
diet (MCDD) to induce FLD. One way that
inflammasomes corrected the imbalance
was through activating IL-1 and IL-18.
Additionally, it was shown that with the
absence of inflammasomes, the gut flora
was not symbiotic and TLRs 4 and 9 were
able to be delivered to the liver. These
TLRs made the FLD worse and exacer-
bated NASH by producing TNF-α, thereby
showing a link between the gut-mediating
inflammasomes and the progression of
NAFLD. The NLRPs seem to work as
gate-keepers in keeping TLR’s normally.
The authors found that mice lacking the
NLRP- inflammasomes, or in other words
did not have the danger-sensing mech-
anism, allowed the habitation of two
abnormal microbial species in their gut,
Prevotella and Porphyromondaceae. Also,
when inflammasome-deficient MCDD
mice were cohabited with wild type
(WT) mice, the dysbiosis and man-
ifestation of disease were transferred
over to the WT mice. Additionally, they
found that the exacerbation of FLD in
the inflammasome-deficient WT mice
did not rely on hematopoietic or hep-
atocyte inflammasomes, implicating an
alternate cell population in controlling
intestinal homeostasis. Since intestinal
epithelial cells possess inflammasomes, it
was concluded that they were the reason
for transfer. IL-18 has previously been
shown to maintain the integrity of these
epithelial cells, and it was shown in this
study, consistent with other studies that an
impaired IL-18 led to an exacerbation of
NAFLD (Elinav et al., 2011).
To investigate the progression of
Metabolic Syndrome, Henao-Mejia
et al., studied an obese mice model, the
leptin-receptor deficient db/db mice that
developed NAFLD, impaired intestinal
barrier function, and glucose intolerance
when fed a high fat diet (HFD). They
found that the db/db mice cohabited
with inflammasome-deficient mice had
an increase in liver disease progression,
including increased hepatocyte injury,
steatosis, and inflammation when com-
pared to db/db mice alone. Furthermore,
the gut flora in HFD mice was involved
in worsening metabolic symptoms, which
include obesity, glucose intolerance, and
insulin resistance. Once again when given
antibiotics, the situation reversed itself.
Previous studies have shown inflamma-
somes to be responsible for inflammatory
destruction, implying that different
inflammasomes carry different func-
tions (Masters, 2013). As mentioned
earlier, IL-18 seems crucial in maintain-
ing homeostasis. IL-1, on the other hand,
is implicated in developing metabolic
disease syndrome and so deemed pro-
inflammatory to worsen the FLD. For
example, Stienstra et al. have found that
in the obese mice, a HFD leads to adi-
pose tissue inflammation by NLRP3
activators like ceramide. The NLRP3-KO
mice were resistant to the development
of HFD-induced obesity, insulin resis-
tance, and hepatic steatosis in an IL-1
dependent manner (Stienstra et al., 2011;
Vandanmagsar et al., 2011). With this
apparent difference between IL-1 and
IL-18, targeting cytokines and inflamma-
somes may prove to be of great therapeutic
benefit.
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This study (Henao-Mejia et al., 2012)
paves the way toward exciting new treat-
ment possibilities for FLD progression and
exacerbation. By looking at the gut-liver
axis it shows that dysbiosis in the gut flora
can be the cause for FLD. Dysbiosis came
about through the absence of NLRP3 and
NLRP6 inflammasomes with the presence
of IL-18. Furthermore, gut flora distur-
bances can occur through a complex inter-
play between genes and the environment.
Maintaining normal gut microbiota might
be the key in stopping the harmful effects
of metabolic syndrome, namely the pro-
gression of inflammatory liver diseases.
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